VIEW OUR PRODUCTS ON

• International, research-based, specialty pharmaceutical company• Discovers, develops, manufactures & markets innovative drug formulations• Develops broad range of modified & immediate release branded and generic tabs/caps• Focus on gastroenterological, cardiovascular & central nervous system diseases• 9 unique, modified release drug delivery technologies, 22 groups of patents• Site delivery/timing enhances efficacy & compliance, reduces side effects

VIEW OUR PRODUCTS: genericlicensing.com/dexel – DIRECT CONTACT

•Established 1968, fully-owned & controlled by President & CEO Dan Oren• 2nd largest Israeli pharma manufacturer• Markets more than 50 branded and generic products in over 140 dosages• Subsidiaries in US, UK & Germany, presence in 19 countries, including Australia• Strategy is "first to file" in the US and "day one" in the EU• First to file, obtained approval for & launch generic Omeprazole OTC in US

VIEW OUR PRODUCTS: genericlicensing.com/dexel – DIRECT CONTACT

•40%+ of UK market for 6 largest products, fastest-growing generic in Germany• Computer-controlled manufacturing technology, US & EU cGMP standards• 2009 sales: 3.9 billion tablets/capsules = $254 million• 2010 sales forecast: 5.4 billion tablets/capsules = $260 million• Approximately 50 products under development, to be launched by 2014

VIEW OUR PRODUCTS: genericlicensing.com/dexel – DIRECT CONTACT

• Facilities comprises a total of 467,000 ft² (=43,380 m²) • Plants in: Or Akiva, Yokneam & Jerusalem• New Yokneam plant: state of the art, paperless, 5-floor gravity feed• Passed US FDA audit (7/10) with no observations, no 483 form• Total investment during 2008-2010 in new facilities: US$65million

VIEW OUR PRODUCTS: genericlicensing.com/dexel – DIRECT CONTACT